DBVT News and Press, DBV Technologies S.A. From 04/08/19

Montrouge, France, April 8, 2019 DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the settlement and delivery of an underwritten global offering of an ...

Montrouge, France, April 5, 2019 DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS) DBV Technologies (the “Compa...

DBV Technologies (NASDAQ: DBVT ) prices its global offering of an aggregate of 5,217,392 ordinary shares, for gross proceeds of ~$70.4M (~€62.7M) More news on: DBV Technologies S.A., DBV Technologies S.A., Healthcare stocks news, Stocks on the move, Read more ...

Montrouge, France, April 4, 2019 DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345...

DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced the filing of its 2018 Annual Report “Document de R...

Aimmune (AIMT) had very good news on Monday, after it had announced a successful phase 3 study from Europe dealing with peanut allergy. The success of this study will allow for a regulatory filing in the European Union in the coming months. The biotech is also awaiting for its review of th...

                                                                                  &#x...

Montrouge, France, March 5, 2019 DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced full year 20...

Montrouge, France, March 5, 2019 DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors Mr. de Rosen to succeed DBV’s co-founder, Dr. Pierre-Henri Benhamou, who will retire from the Board of Directors and join Scientific ...

Montrouge, France, March 1, 2019 DBV Technologies to Attend Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that members of its management team w...